EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications

Nyein Wint Yee Theik, Suset Almuinas De Armas, Daniel Rosas iD, Amy Kiamos iD, Nyein Nyein Thaw Dar, Ahmed Shoreibah, Atif Hussein, Luis E Raez iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26083802 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nyein Wint Yee Theik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Healthcare System, Internal Medicine Residency Program, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Oncogene Proteins, Fusion, Oncogene Fusion. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) is operated commonly by diverse genetic alterations, and oncogenic fusions represent a significant therapeutic role. Common fusions include ALK, ROS1, RET, and NTRK, signaling pathways in tumorigenesis. Recent advances in investigating tumor molecular biology include underlying fusions, including chromosomal rearrangements, highlighting their role as oncogenic drivers. The development of targeted therapies, such as tyrosine kinase inhibitors (TKIs), has impacted most patients’ NSCLC treatment. Despite the greater profiles, such as remarkable efficiency and tolerable side effects compared to traditional chemotherapy, challenges, such as acquired mutations, lead to more ongoing research-optimized future NSCLC therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsOncogene Proteins, FusionOncogene FusionHumansProtein Kinase InhibitorsAnaplastic Lymphoma KinaseMolecular Targeted TherapyAnimalsProtein-Tyrosine KinasesProto-Oncogene Proteins

Stichwörter der Autor:innen

ALKNSCLCNTRKRETROS1TKImutationoncogenic driver

Substanzen

Oncogene Proteins, FusionProtein Kinase InhibitorsROS1 protein, humanAnaplastic Lymphoma KinaseProtein-Tyrosine KinasesProto-Oncogene Proteins

Autor:innen und Institutionen

  • Memorial Healthcare System, Internal Medicine Residency Program, Pembroke Pines, FL 33028, USA.
  • Memorial Cancer Institute, Memorial Healthcare System, Hematology-Oncology Fellowship Program, Pembroke Pines, FL 33028, USA.
  • Memorial Cancer Institute, Memorial Healthcare System, Florida Atlantic University (FAU), Hollywood, FL 33021, USA.
  • Thoracic Oncology Program, Memorial Cancer Institute (MCI), Florida Atlantic University (FAU), Hollywood, FL 33021, USA.

ORCID-Profile: Daniel Rosas, Amy Kiamos, Luis E Raez

Zitieren

APA

Theik, N. W. Y., De Armas, S. A., Rosas, D., Kiamos, A., Thaw Dar, N. N., Shoreibah, A., Hussein, A., & Raez, L. E. (2025). Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083802

Vancouver

Theik NWY, De Armas SA, Rosas D, Kiamos A, Thaw Dar NN, Shoreibah A, et al. Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083802

BibTeX
@article{Theik2025,
  author = {Theik, Nyein Wint Yee and De Armas, Suset Almuinas and Rosas, Daniel and Kiamos, Amy and Thaw Dar, Nyein Nyein and Shoreibah, Ahmed and Hussein, Atif and Raez, Luis E},
  title = {Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26083802}
}
Kostenlos starten →